COLGATE PALMOLIVE CO
Colgate-Palmolive makes and markets consumer products for people and pets. It operates two segments: Oral, Personal and Home Care, and Pet Nutrition. Oral Care products include toothpastes, toothbrushes, mouthwashes and pharmaceutical products for dentists and other oral health professionals. Personal Care includes soaps, shower gels, deodorants, antiperspirants and skin health products; Home Care includes dishwashing liquids, household cleaners and fabric conditioners. These products are sold under brands including Colgate, Palmolive, Softsoap, Ajax and Fabuloso. Through Hill’s Pet Nutrition, Colgate-Palmolive sells dog and cat foods, including Hill’s Science Diet, Hill’s Prescription Diet and Prime100. Its products are marketed in over 200 countries and territories. Oral, Personal and Home Care products are sold to retailers, wholesalers and distributors worldwide; pet products are sold through authorized pet supply retailers, veterinarians and eCommerce retailers. Some products are also sold direct-to-consumer. Colgate-Palmolive is headquartered in New York, NY.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Colgate-Palmolive (CL) raised its 2026 outlook and reported Q3 results, with shares up 11.12% in the past month and 26.26% year-to-date. Analysts debate valuation, with one model suggesting a 13% overvaluation at $86.48, while another DCF model values shares at $125.78, 22% above current price.
NORRINGTON LORRIE M sold 4,170 shares of COLGATE PALMOLIVE CO (CL) at $99.31 ($0.41M total) on 2026-11-05.
Colgate-Palmolive insiders sold shares worth over $6.2M. Chief Growth Officer Hazlin John sold 23,376 shares at $99.15 each, COO Tsourapas Panagiotis sold 19,938 shares at $98.74, and CEO Noel R. Wallace sold 20,000 shares at $100.26. The transactions reduced their direct and indirect holdings.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning CL (COLGATE PALMOLIVE CO). Coverage has skewed bullish: 2 bullish, 1 neutral, and 1 bearish.
Recent CL coverage spans insider activity, financial news and earnings.
In the last 30 days, CL insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($6.7M). The most active reporter was NORRINGTON LORRIE M with 1 filing.
The guidance upgrade is already priced in; the commentary may prompt short‑term caution.
Insider selling is unlikely to be a standalone catalyst, but it can modestly affect near-term sentiment if traders interpret it as reduced confidence.
The insider sales may signal reduced confidence and could weigh on the stock.
Insider sale by the chief executive may signal modest concern and could weigh on the stock.
The insider sale modestly increases supply of CL shares and may signal personal liquidity needs, but the amount is small relative to market cap.
AlphAI scores every news story that mentions CL with an AI model for sentiment and relevance, and aggregates insider trades from COLGATE PALMOLIVE CO's SEC EDGAR Form 4 filings. Figures refresh continuously.
Colgate-Palmolive (CL) raised its 2026 outlook and reported Q3 results, with shares up 11.12% in the past month and 26.26% year-to-date. Analysts debate valuation, with one model suggesting a 13% overvaluation at $86.48, while another DCF model values shares at $125.78, 22% above current price.
NORRINGTON LORRIE M sold 4,170 shares of COLGATE PALMOLIVE CO (CL) at $99.31 ($0.41M total) on 2026-11-05.
Colgate-Palmolive insiders sold shares worth over $6.2M. Chief Growth Officer Hazlin John sold 23,376 shares at $99.15 each, COO Tsourapas Panagiotis sold 19,938 shares at $98.74, and CEO Noel R. Wallace sold 20,000 shares at $100.26. The transactions reduced their direct and indirect holdings.
Wallace Noel R. (Chairman, President & CEO) sold 20,000 shares of COLGATE PALMOLIVE CO (CL) at $100.26 ($2.01M total) on 2026-11-05.
Tsourapas Panagiotis (COO, CD, EMEA, APac, Skin) sold 19,938 shares of COLGATE PALMOLIVE CO (CL) at $98.74 ($1.97M total) on 2026-11-04.
Hazlin John (Chief Growth Officer) sold 23,376 shares of COLGATE PALMOLIVE CO (CL) at $99.15 ($2.32M total) on 2026-11-04.
Global FMCG companies report strong growth in India amid sluggish demand in China and Europe. Unilever, Nestle, and others highlight India's double-digit growth and expansion potential. Despite rising inflation, companies are investing heavily in India, with Unilever committing €35 million for R&D. The IMF and World Bank raised India's GDP growth forecasts to 7% for FY27.
Procter & Gamble (PG) and Colgate-Palmolive (CL) both beat earnings expectations. PG reported Q1 FY2027 core EPS of $2.00, with organic sales up 4.0%, driven by volume. CL beat with EPS of $0.97, with organic growth of 3.6%, driven by pricing. PG's dividend yield is 2.6%, while CL's is 2.1%. PG's cash flow comfortably covers its dividend, while CL's equity has thinned due to repurchases. CL shares are up 29.3% YTD, versus 21.33% for PG.
Colgate-Palmolive (CL) surged 12.3% in October, outperforming its peers and the sector ETF. The company reported 3% EPS growth and 3.6% organic sales growth in Q3, raising its full-year revenue guidance to 4-5%. It is considered a strong long-term investment due to its 63-year dividend-hiking streak and defensive stock properties.
Colgate-Palmolive will pay a $930,000 penalty to the EPA for failing to report 47 chemicals imported between 2016 and 2019, as required by the Toxic Substances Control Act. The company submitted the data in July 2023 and has since certified compliance. The EPA uses this data to assess chemical impacts on health and the environment.
